PASSION FOR IDEAS
life sciences: current investments*
 BIND Biosciences
Bind Biosciences (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles.
 CeQur
Medical Technology company developing a device to improve the care of type 2 diabetic patients.
 Endotis Pharma
Discovery and development of SGDs (small glycan drugs) to provide the patient with safer and more efficient anti-thrombotics.
 Kuros Biosurgery
Biomaterials and bioactives for chronic wounds and bone regeneration.
 Lumavita
Lumavita is a biotech-pharma company based in Basel, Switzerland, specialising in Woman’s Health.
 Molecular Partners
Molecular Partners is developing a novel class of binding proteins (DARPins) that will compete with monoclonal antibodies by addressing some of their weaknesses.
 Neocutis
Neocutis is a spin-off from the CHUV hospital in Lausanne, focused on innovative dermatology, skin care, wound healing treatment and cosmetics.
 Novalar
Mid-stage specialty pharmaceutical company in dental market. The Novalar product (a vasodilatator), rapidly reverses the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.
 Novimmune
Drug develpment company focused on the new therapies for immune-related disorders and inflammation.
 OncoEthix
OncoEthix is a drug development company dedicated to the development of compounds in oncology.




life sciences: previous investments*
 Actelion
Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.
 Axovan
Founded in April 2000. Discovery and development of small molecules active on novel G protein-coupled receptors. CHF38 Mio raised, 60 employees. Most advanced project (Phase II): sub-arachnoid haemorrhage. Acquired by Actelion (ATLN) in October 2003.
 EndoArt
Medical technology company with a device to treat morbid obese patients. A gastric band restricts food intake, and is remotely controlled by the medical doctor. Company sold to Allergan (AGN) in February 2007.
 GeneSystems
Fully automated system for molecular biology diagnostis enablking easy DNA extraction and fast detection of bacteria.
 Paion
Indications of stroke and the related indications neuronal damage and thrombotic disease. IPO on Frankfurt exchange (PA8) in February 2005.
 Thommen Medical
Develop, manufacture, and market dental implant systems. Sold participation in January 2006.




*) includes investment advised by Endeavour, Vision & Genevest
partner of the European Tech Tour "Endeavour works with their CEOs to help them make the right moves at the right time, on every side of the management of the company : organization and people, financials, partnerships, technology investment, sales and marketing. This makes them a real help for the CEO as we can discuss not only financials, but more importantly operational and business matters intelligently and efficiently, with a very strong bias toward results"
Jacques Clay, Executive Chairman, Polyspace Technologies SA